NASDAQ:CLDXCelldex Therapeutics Stock Price, Forecast & News

Celldex Therapeutics' stock was trading at $2.03 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, CLDX stock has increased by 399.0% and is now trading at $10.13.
View which stocks have been most impacted by COVID-19.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Celldex Therapeutics in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Celldex Therapeutics.

Celldex Therapeutics is scheduled to release its next quarterly earnings announcement on Tuesday, November 10th 2020.
View our earnings forecast for Celldex Therapeutics.

Celldex Therapeutics, Inc. (NASDAQ:CLDX) issued its quarterly earnings data on Thursday, August, 6th. The biopharmaceutical company reported ($0.50) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.58) by $0.08. Celldex Therapeutics had a negative net margin of 1,035.16% and a negative return on equity of 35.18%.
View Celldex Therapeutics' earnings history.

Celldex Therapeutics shares reverse split before market open on Monday, February 11th 2019. The 1-15 reverse split was announced on Friday, February 8th 2019. The number of shares owned by shareholders was adjusted after the closing bell on Friday, February 8th 2019. An investor that had 100 shares of Celldex Therapeutics stock prior to the reverse split would have 7 shares after the split.

2 brokerages have issued 1 year price objectives for Celldex Therapeutics' stock. Their forecasts range from $16.00 to $18.00. On average, they expect Celldex Therapeutics' stock price to reach $17.00 in the next year. This suggests a possible upside of 67.8% from the stock's current price.
View analysts' price targets for Celldex Therapeutics.

Press coverage about CLDX stock has trended extremely negative on Thursday, according to InfoTrie. The research firm identifies positive and negative media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Celldex Therapeutics earned a media sentiment score of -4.1 on InfoTrie's scale. They also gave press coverage about the biopharmaceutical company a news buzz of 10.0 out of 10, meaning that recent media coverage is extremely likely to have an impact on the company's share price in the near term.
View the latest news about Celldex Therapeutics.

Celldex Therapeutics saw a decrease in short interest in the month of May. As of May 15th, there was short interest totaling 264,200 shares, a decrease of 13.9% from the April 30th total of 306,700 shares. Based on an average daily trading volume, of 385,200 shares, the days-to-cover ratio is currently 0.7 days.
View Celldex Therapeutics' Short Interest.

Some companies that are related to Celldex Therapeutics include Amgen (AMGN), Gilead Sciences (GILD), Celgene (CELG), Vertex Pharmaceuticals (VRTX), Regeneron Pharmaceuticals (REGN), Biogen (BIIB), Seattle Genetics (SGEN), Alexion Pharmaceuticals (ALXN), BioMarin Pharmaceutical (BMRN), Incyte (INCY), Alnylam Pharmaceuticals (ALNY), EXACT Sciences (EXAS), Neurocrine Biosciences (NBIX), Immunomedics (IMMU) and Novavax (NVAX).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Celldex Therapeutics investors own include Opko Health (OPK), Gilead Sciences (GILD), Corbus Pharmaceuticals (CRBP), ACADIA Pharmaceuticals (ACAD), Micron Technology (MU), Precigen (PGEN), Dynavax Technologies (DVAX), Chesapeake Energy (CHKAQ), Chesapeake Energy (CHKAQ) and Exelixis (EXEL).

Celldex Therapeutics trades on the NASDAQ under the ticker symbol "CLDX."

Celldex Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include TSP Capital Management Group LLC (1.63%), Monashee Investment Management LLC (1.33%), Granite Point Capital Management L.P. (0.48%), Creative Planning (0.16%), WINTON GROUP Ltd (0.09%) and Mirador Capital Partners LP (0.08%). Company insiders that own Celldex Therapeutics stock include Anthony S Marucci, Diane C Young, James J Marino, Margo Heath-Chiozzi, Samuel Bates Martin and Tibor Keler.
View institutional ownership trends for Celldex Therapeutics.

CLDX stock was sold by a variety of institutional investors in the last quarter, including TSP Capital Management Group LLC, and Raymond James Financial Services Advisors Inc..
View insider buying and selling activity for Celldex Therapeutics.

CLDX stock was acquired by a variety of institutional investors in the last quarter, including Monashee Investment Management LLC, Granite Point Capital Management L.P., Creative Planning, Mirador Capital Partners LP, and WINTON GROUP Ltd. Company insiders that have bought Celldex Therapeutics stock in the last two years include Anthony S Marucci, Diane C Young, James J Marino, Margo Heath-Chiozzi, Samuel Bates Martin, and Tibor Keler.
View insider buying and selling activity for Celldex Therapeutics.

Shares of CLDX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of CLDX stock can currently be purchased for approximately $10.13.

Celldex Therapeutics has a market capitalization of $228.48 million and generates $3.57 million in revenue each year. The biopharmaceutical company earns $-50,880,000.00 in net income (profit) each year or ($3.28) on an earnings per share basis. Celldex Therapeutics employs 133 workers across the globe.

The official website for Celldex Therapeutics is www.celldex.com.

Celldex Therapeutics' mailing address is 53 FRONTAGE ROAD SUITE 220, HAMPTON NJ, 08827. The biopharmaceutical company can be reached via phone at 908-200-7500 or via email at [email protected]